Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs
- Tyra Biosciences (TYRA) has priced an underwritten offering of common stock and pre-funded warrants for gross proceeds of approximately $400.0 million.
- The offering consists of 9,079,000 shares of common stock at $22.03 per share and, in lieu of shares for certain investors, 9,078,529
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.